Macular Degeneration Market to Reach USD 21.5 Billion by 2034, Growing at 8.1% CAGR

Subheadline:
Rising global prevalence of age-related macular degeneration (AMD), expansion of biologic treatment portfolios, and the integration of AI-based screening tools are driving substantial market growth.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72648

Introduction
The Macular Degeneration Market is entering a transformative era marked by breakthroughs in anti-VEGF biologics, gene therapy, and AI-powered retinal imaging.
Valued at USD 10.1 billion in 2024, the global market is projected to reach USD 21.5 billion by 2034, growing at a CAGR of 8.1% during the forecast period.

Macular degeneration-especially age-related macular degeneration (AMD)-is one of the leading causes of irreversible vision loss among the elderly. As populations age and awareness of early diagnosis rises, healthcare systems are prioritizing retinal disease management through advanced biologics and smart diagnostic ecosystems.

Key Players in the Market
The market features leading pharmaceutical innovators, biotech firms, and ophthalmology specialists pioneering next-generation retinal therapies.

Major players include:
• Roche Holding AG (Genentech Inc.)
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Bayer AG
• Apellis Pharmaceuticals Inc.
• Kodiak Sciences Inc.
• Outlook Therapeutics Inc.
• Adverum Biotechnologies Inc.
• Samsung Bioepis
• Allergan plc (AbbVie Inc.)

These players are expanding their treatment pipelines through long-acting anti-VEGF biologics, gene therapy delivery systems, and sustained-release implants designed to minimize patient burden.

Key Events in the Last Five Years
• 2020-2021: FDA approvals of next-generation anti-VEGF agents such as Beovu (Novartis) and Eylea high-dose (Regeneron) improved dosing intervals and patient adherence.
• 2022: Roche received FDA approval for Vabysmo (faricimab)-the first bispecific antibody for both wet AMD and diabetic macular edema.
• 2023: Apellis Pharmaceuticals launched SyfovreTM, the first FDA-approved therapy for geographic atrophy, addressing a major unmet need in late-stage dry AMD.
• 2024: AI-based diagnostic tools for retinal imaging gained traction, improving early detection and real-time disease monitoring.

Market Growth Rate
According to Exactitude Consultancy, the macular degeneration market will register a CAGR of 8.1% (2025-2034), fueled by:
• Increasing geriatric population and AMD prevalence.
• Rapid innovation in biologic drug delivery systems (implants, sustained release).
• Gene therapy approvals enabling long-lasting treatment with fewer injections.
• Growth in AI-assisted screening and teleophthalmology programs.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72648/macular-degeneration-market

Market Segments and Growth Analysis
The market is segmented by type, treatment, and region.
By Type:
• Dry (Atrophic) AMD
• Wet (Neovascular) AMD

By Treatment:
• Anti-VEGF Drugs (Ranibizumab, Aflibercept, Bevacizumab, Faricimab)
• Complement Inhibitors (Pegcetacoplan, Avacincaptad Pegol)
• Gene Therapy (AAV-based delivery)
• Stem Cell Therapy and Regenerative Implants
• Combination and Sustained-Release Therapies

By Region:
• North America: Largest market share; advanced biologics access and strong reimbursement frameworks.
• Europe: Increasing adoption of AI diagnostics and biosimilar ophthalmics.
• Asia Pacific: Fastest-growing region due to higher AMD awareness and expanding retinal-care infrastructure in Japan, India, and China.
• Latin America & MEA: Improving access to biologic therapies via public health partnerships.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72648

Key Market Drivers
1. Innovation in Biologics and Delivery Systems:
New bispecific antibodies and sustained-release technologies reduce injection frequency and improve outcomes.
2. Rise of AI in Ophthalmology:
Deep-learning algorithms enable early disease prediction, segmentation, and progression tracking.
3. Gene and Cell Therapies:
Single-administration treatments targeting complement pathways and retinal pigment epithelium regeneration are reshaping the therapeutic landscape.
4. Aging Demographics:
By 2030, one in six people globally will be over 60, significantly expanding the patient base.

Recent Developments
• 2023: Apellis Pharmaceuticals achieved commercial success with SyfovreTM for geographic atrophy, marking a milestone in dry AMD treatment.
• 2024: Kodiak Sciences reported strong Phase III data for KSI-301, a long-acting anti-VEGF antibody biopolymer conjugate.
• 2024: Roche expanded Vabysmo's indication for diabetic retinopathy, strengthening its retinal franchise.
• 2024: Adverum Biotechnologies advanced a gene therapy candidate for intravitreal injection offering multi-year efficacy from a single dose.

Expert Insight
"Macular degeneration research is accelerating faster than ever. The convergence of biologics, gene therapy, and AI is leading us toward a future where blindness from AMD could become preventable,"
- Dr. Emily Hartmann, Professor of Ophthalmology, Johns Hopkins University.

Conclusion
The Macular Degeneration Market is at a critical inflection point, driven by biologic innovation, complement-pathway therapeutics, and digital imaging advancements.

As regulatory approvals and reimbursement expand, next-generation therapies promise to transform long-term outcomes for millions affected by AMD.
By 2034, the market will stand as a cornerstone of precision ophthalmology-where gene-driven therapies, sustained delivery, and predictive AI platforms work together to preserve vision for life.

This report is also available in the following languages : Japanese (黄斑変性市場), Korean (황반변성 시장), Chinese (黄斑变性市场), French (Marché de la dégénérescence maculaire), German (Markt für Makuladegeneration), and Italian (Mercato della degenerazione maculare), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72648

Our More Reports:

Cholangiosarcoma Market
https://exactitudeconsultancy.com/reports/72868/cholangiosarcoma-market

TCR Therapy Market
https://exactitudeconsultancy.com/reports/72878/tcr-therapy-market

Immunocytokines Market
https://exactitudeconsultancy.com/reports/72888/immunocytokines-market

Radiopharmaceutical Manufacturing Market
https://exactitudeconsultancy.com/reports/72906/radiopharmaceutical-manufacturing-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.